Contraceptive use following diagnosis of gestational trophoblastic disease or gestational trophoblastic neoplasia is key to allow for careful monitoring of beta-hCG without the risk of new incident pregnancy. However there is lack of clarity regarding risks and benefits of different contraceptive methods to help guide patient and provider shared decision making on this topic. Our aim was to systematically review the effect of contraceptive methods following gestational trophoblastic disease (GTD) on timing of beta-hCG remission risk of post-molar gestational trophoblastic neoplasia (GTN) risk of unintended incident pregnancy and interactions between contraceptive methods and disease treatment. Our findings suggest that hormonal contraception does not have an impact on beta-hCG normalization or the risk of developing post-molar gestational trophoblastic neoplasia. There was insufficient data to comment on interactions with cancer-directed treatment.
